State-of-the-art drug-eluting metal stents are the gold standard for interventional treatment of
coronary artery disease. Although they overcome some disadvantages and limitations of …

Current generation of drug-eluting stents has significantly improved the outcomes of
percutaneous coronary intervention by substantially reducing in-stent restenosis and stent …

Background Recent reports suggest an elevated incidence of bioresorbable vascular
scaffold (BVS) thrombosis (scaffold thrombosis [ScT]). Objectives This study investigated …

Abstract Aims Bioresorbable vascular scaffolds (BVSs) have been studied in chronic
coronary artery disease, but not in acute ST-segment elevation myocardial infarction …

Aims We evaluated the feasibility and the acute performance of the everolimus-eluting
bioresorbable vascular scaffolds (BVS) for the treatment of patients presenting with ST …

Aims: The Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) represents an
important advance in percutaneous coronary intervention (PCI) technology. With increasing …

Aims: Bioresorbable vascular scaffolds (BVS) have been available on the European market
since November 2011. The ASSURE registry aims to investigate the safety and efficacy of …

Aims: Recent studies have demonstrated favourable clinical outcomes for the everolimus-
eluting bioresorbable vascular scaffold (BVS) ABSORB™ in patients with stable coronary …

Aims: In this multicentre prospective registry we sought to evaluate the immediate and
midterm clinical outcomes following single or multiple overlapping bioresorbable vascular …

Objectives: This is the first-in-human study of a drug-eluting bioresorbable vascular scaffold
(BVS) for treatment of peripheral artery disease (PAD) involving the external iliac artery (EIA) …